Ozanimod (Zeposia®)
Publisert:
Sist revidert av:Hanne Marie Bøe Lunde
Kort om
Indikasjon
Informasjonsmateriell
Effekt
Dosering
Bivirkninger
Kontraindikasjoner
Før behandling
Ved første dose
Kontroller under behandling
Seponering
Etter avsluttet behandling
Kilder
Referanser
- Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009-20. PubMed
- Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021-33. PubMed
- Zeposia - Summary of Product Characteristics Available from: https://www.ema.europa.eu/documents/product-information/zeposia-epar-product-information_no.pdf.
- Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, et al. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. J Clin Pharmacol. 2017;57(8):988-96. PubMed
- Hanne Marie Bøe Lunde, spesialist i nevrologi PhD
- Åse Mygland, spesialist i nevrologi, professor dr med
- Unn Ljøstad, spesialist i nevrologi, professor PhD